Abstract 2597
Background
Cancer holds a huge psychosocial impact. Understanding the diagnosis and treatment gives cancer patients a feeling of autonomy and self-control. The patients’ perspective and expectations on the qualities of a medical oncologist are still poorly known.
Methods
Observational cross-sectional study of cancer patients observed in a Portuguese peripheral hospital in October 2018. When patients knew the primary tumour site, stage of disease and intent of treatment they were considered to have “Full knowledge”. Descriptive statistics and univariate analysis were performed, considering a CI of 95%.
Results
Seventy-two patients were included. Most were men (56.9%), with a median age of 60 years and 65.3% had an ECOG PS of 1. Patients reported feelings of shock (43.0%), sadness (38.9%), fear (34.7%) and courage (33.3%) when they became aware of their oncological diagnosis. About 12.5% of patients needed evaluation by Psychology/Psychiatry on the first 3 months after diagnosis, of which 2/3 had a history of depressive or anxiety disorders. The majority of patients (78%) received the diagnosis in a consultation, 12.5% in the emergency department with 4.2% being informed by their relatives (4.2%). About 90% of patients stated they knew their diagnosis while 5.6% were not sure. Correct identification of the primary tumour site occurred in 87% of patients and 81.9% knew the disease stage. Of those under treatment (n = 58), almost 20% did not understand its intention. About 54% of patients had "full knowledge" of the disease and treatments. There was no significant correlation between socio-demographic and clinical variables and "full knowledge" of the disease, and only age approached the significance level (p = 0.083). Patients mostly valued kindness (62.5%), honesty (55.6%) and knowledge (47.2%) in a medical oncologist.
Conclusions
Despite the majority of patients claiming to be aware of their disease, almost half did not understand the disease stage or treatment intention. Clear communication can contribute to a greater sense of knowledge, autonomy and adaptation to the disease, potentially influencing quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract